Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today provided an update on the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) and reported other business updates and financial results for the third quarter ended September 30, 2025.

Read more at globenewswire.com